We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App





Ultra-Fast COVID-19 PCR Test to Achieve High Accuracy at Speed 20 Times Faster than Lab-Based PCR Tests

By LabMedica International staff writers
Posted on 22 Nov 2021

An ultra-fast COVID-19 PCR test developed for point-of-care use combines the accuracy of central lab-based PCR testing with the speed of self-testing. More...

miDIAGNOSTICS (Leuven, Belgium) has developed a rapid COVID-19 PCR test that has the potential to achieve an excellent accuracy at a speed 20 times faster than ‘classic’ PCR machines in labs. The test, based on the company’s highly innovative diagnostics platform, involves the transfer of a nasopharyngeal swab sample on a PCR test card, from which the results are read by a compact reader.

The COVID-19 pandemic has underscored the importance of abundant and accurate diagnostics. It will still take quite some time before herd immunity will be achieved worldwide, and ongoing virus mutations and new variants pose major challenges to the vaccination process. Meanwhile, there is a great need for rapid accurate tests that can be performed at airports, in the workplace, at events, in doctors’ offices, or even at home. Unfortunately, rapid COVID-19 tests often have limited accuracy, while reliable diagnostic tests, based on PCR analysis and performed in central laboratories, can take anywhere from several hours to several days from a sample collection to a test result.

Enabled by miDIAGNOSTICS’ silicon chip technology, its ultra-fast PCR COVID-19 test combines the speed of a rapid antigen test with the performance of trusted PCR-based testing. The company’s ultra-fast COVID-19 PCR test will take 15 minutes from sample to result. Testing can be easily scaled up with the combination of multiple readers, because of the short turnaround time of 15 minutes, enabling simultaneous high throughput in many decentralized settings where highly accurate testing is desired, including at airports, offices, schools, events or any other local healthcare setting. Beyond COVID-19, the platform has the potential to be reconfigured for diagnosing other infectious diseases, as needed.

Related Links:
miDIAGNOSTICS 


Gold Member
Universal Transport Solution
Puritan®UniTranz-RT
POC Helicobacter Pylori Test Kit
Hepy Urease Test
CBM Analyzer
Complete Blood Morphology (CBM) Analyzer
8-Channel Pipette
SAPPHIRE 20–300 µL
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Original illustration showing how exposure-linked mutation patterns may influence tumor immune visibility (Photo courtesy of Máté Manczinger, HUN-REN Szeged BRC)

Cancer Mutation ‘Fingerprints’ to Improve Prediction of Immunotherapy Response

Cancer cells accumulate thousands of genetic mutations, but not all mutations affect tumors in the same way. Some make cancer cells more visible to the immune system, while others allow tumors to evade... Read more

Industry

view channel
Image: The initiative aims to speed next-generation diagnostic development during early pathogen emergence (photo courtesy of 123RF)

Cepheid Joins CDC Initiative to Strengthen U.S. Pandemic Testing Preparednesss

Cepheid (Sunnyvale, CA, USA) has been selected by the U.S. Centers for Disease Control and Prevention (CDC) as one of four national collaborators in a federal initiative to speed rapid diagnostic technologies... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.